Clinical Trial Update: The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial sponsored by Fudan University is evaluating Narlumosbart in combination with SBRT as part of first-line chemotherapy and immunotherapy …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Narlumosbart

Snippet

Sponsor: Fudan University | Conditions: NSCLC, Stereotactic Body Radiation Therapy (SBRT) | Phase 2 | Status: RECRUITING